Lentigo

Summary

Lentigo (MONDO:0021582) is a disease and 11 clinical trials. Top therapeutic interventions include tretinoin. A subtype of hereditary skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lentigo
Mondo ID	MONDO:0021582
MeSH	D007911
OMIM	150900
NCIT	C3159
SNOMED CT	402624000
UMLS	C0023321
MedGen	7301
Is cancer (heuristic)	no

Also known as: lentigines · lentiginosis · lentigo

Disease family

This is a subtype of hereditary skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary skin disorder › lentigo

Related subtypes (113): alopecia, isolated, reticulate pigment disorder, dyschromatosis universalis hereditaria, psoriasis, porokeratosis, hereditary papulotranslucent acrokeratoderma, acrokeratosis verruciformis, Tietz syndrome, familial primary localized cutaneous amyloidosis, isolated anhidrosis with normal sweat glands, aplasia cutis congenita, blue rubber bleb nevus, Darier disease, dermatosis papulosa nigra, autosomal dominant vibratory urticaria, absence of fingerprints-congenital milia syndrome, pilomatrixoma, spinocerebellar ataxia type 34, isolated congenital adermatoglyphia, isolated hyperchlorhidrosis, hyperkeratosis-hyperpigmentation syndrome, hyperpigmentation with or without hypopigmentation, familial progressive, lichen sclerosus et atrophicus, lichen planus, familial, monilethrix, hereditary mucoepithelial dysplasia, schwannomatosis, nevus, epidermal, familial multiple nevi flammei, linear nevus sebaceous syndrome, progressive osseous heteroplasia, Hailey-Hailey disease, piebaldism, familial pityriasis rubra pilaris, scalp defects-postaxial polydactyly syndrome, seborrheic keratosis, Sneddon syndrome, sebocystomatosis, stiff skin syndrome, familial multiple discoid fibromas, urticaria, aquagenic, urticaria, familial localized heat, vasculitis, lymphocytic, nodular, VPS13A-related neurodegenerative disease, acrogeria, anhidrosis, familial generalized, with abnormal or absent sweat glands, deafness, congenital, with total albinism, epidermodysplasia verruciformis, combined immunodeficiency with skin granulomas, lipoid proteinosis, neurocutaneous melanocytosis, neutrophil actin dysfunction, albinism-hearing loss syndrome, X-linked reticulate pigmentary disorder, CHILD syndrome, linear skin defects with multiple congenital anomalies, dermatitis herpetiformis, familial, keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome, H syndrome, hydroa vacciniforme, familial, poikiloderma with neutropenia, acne, infundibulocystic basal cell carcinoma, Becker nevus syndrome, generalized basaloid follicular hamartoma syndrome, sweet syndrome, MEDNIK syndrome, seborrhea-like dermatitis with psoriasiform elements, DK1-congenital disorder of glycosylation, body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency, Legius syndrome, CLOVES syndrome, encephalocraniocutaneous lipomatosis, familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome, Maffucci syndrome, hereditary sclerosing poikiloderma with tendon and pulmonary involvement, cardiomyopathy, dilated, with wooly hair, keratoderma, and tooth agenesis, skin creases, congenital symmetric circumferential, 2, nevus comedonicus syndrome, severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome, chronic mucocutaneous candidiasis, segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome, hereditary mucosal leukokeratosis, inherited ichthyosis, hereditary photodermatosis, Cowden disease, juvenile hyaline fibromatosis, osteopathia striata-pigmentary dermopathy-white forelock syndrome, syndromic oculocutaneous albinism, phakomatosis pigmentokeratotica, neonatal inflammatory skin and bowel disease, lamellar ichthyosis, PENS syndrome, familial multiple fibrofolliculoma, autosomal recessive cutis laxa type 2A, familial chilblain lupus, familial keratoacanthoma, keratosis pilaris atrophicans, Cobb syndrome, oculocutaneous albinism, hereditary palmoplantar keratoderma, inherited epidermolysis bullosa, ectodermal dysplasia syndrome, subcutaneous panniculitis-like T-cell lymphoma, hereditary angioedema, hereditary lipodystrophy, X-linked chondrodysplasia punctata 2, multiple benign circumferential skin creases on limbs 1, familial acne inversa, familial acanthosis nigricans, large congenital melanocytic nevus, familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome, inflammatory poikiloderma with hair abnormalities and acral keratoses

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Hydroquinone	Approved (phase 4)
Tazarotene	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE4	1
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05471947	PHASE4	COMPLETED	TCA 15% Chemical Peel for Improvement in Hand Lentigines
NCT00975312	PHASE2	COMPLETED	Solar Lentigines Treatment With the Triple Combination Cream
NCT02427724	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Effect of Topical Anesthetics on Patients’ Pain and Operative Experience During Treatment With QSwitched Laser
NCT01136629	Not specified	UNKNOWN	Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion
NCT02385994	Not specified	COMPLETED	A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin
NCT02492373	Not specified	COMPLETED	Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser
NCT02763072	Not specified	COMPLETED	A Single-Center 2-Arm Study for Lentigines on the Hands
NCT03457246	Not specified	COMPLETED	Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands’ Lentigo Lesions With or Without Laser Therapy
NCT06046144	Not specified	COMPLETED	Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
NCT06305897	Not specified	UNKNOWN	Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face
NCT06361251	Not specified	COMPLETED	Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRETINOIN	4	1